TNFis preventing cancer compared to placebo, and JAKi being neutral to placebo and maybe preventing haem cancers also. #ACR24 abstract 0989 was certainly provocative. I've shared my thoughts on @RheumNow https://t.co/yQFoUGifEN

• Do TNFis and JAKis Prevent Cancer!? | RheumNow

Potential Impact of Weight Loss Drugs in Rheumatic Diseases Dr. Arthur Kavanaugh highlights a session regarding weight loss and improvement in disease outcomes, specific weight loss drugs (SGL-2 and GLP-1), along with downsides when patients stop these medications. Reporting… https://t.co/Ilu2FXK2xi https://t.co/7CKSnfuey4

A#2651 Vasculitis w VEXAS 81 men, median age 67 - 27% had evid of vasculitis, variable size vessel 22% SVV- 17/18 cutaneous, one peritubular capillaritis on renal bx 2.5% MVV (2 cutan), LVV (2 carotid thickening, 1 had +TA bx), ANCA+ @RheumNow #ACR24 https://t.co/puablIBLCP

• https://x.com/ericdeinmd/status/1858616964383375444/photo/1

What factors are assoc with uptake of newer meds in RA? ➡️Incr use of b/tsDMARDs over 10yrs ➡️Use of newer drugs lower in older ppl, socioeconomic deprived & Asian/Black ppl Could this indicate disparities in access to meds? How can we best address this? Ab2608 #ACR24 @RheumNow

A#2652 NEWTON study 🇫🇷 Retrosp cohort 51% relapse. Median @8.7 mos, dose 9mg pred Rf: limb art involv- HR 1.9 Pred taper speed not risk for relapse Most relapse -> incr GCs Toci 1/3 at dx, 50% stopped -61% d/c due to remission, 39% SEs -1/3 relapse after d/c @RheumNow #ACR24 https://t.co/NP0wieDmvo

• https://x.com/ericdeinmd/status/1858620704528146555/photo/1

Peyrac et al. 211 GCA. Relapse in 52% at median 261 days (so 1st year). 83% on GCs at relapse, median dose 6.5mg pred. 36% relapse post-toc discontinuation, at median 133 days. 64% no relapse when toc stopped, at median 511 days @RheumNow #ACR24 Abstr#2652 https://t.co/NqtdDNGGoc https://t.co/mXD8x7O6Ww

• You searched for Characteristics of Relapse and Therapeutic Management in Giant…
• https://x.com/RichardPAConway/status/1858621703745925264/photo/1

A#2648 PET for GCA Delayed imaging at 180 min improve dx performance for pts on GCs Optimal PET w/in 3 days of GC, most patients unable to do w/in that window Delay has sensitivity 92% even on prednisone - may be good tool for pts unable to get early PET/CT #ACR24 @RheumNow https://t.co/kxpNfRqkGN

• https://x.com/ericdeinmd/status/1858606871726395589/photo/1
• https://x.com/ericdeinmd/status/1858606871726395589/photo/1
• https://x.com/ericdeinmd/status/1858606871726395589/photo/1

Study by Maria Dall'Era et al. compared voclosporin-based triple immunosuppressive therapy with high-dose GC in active lupus nephritis. - Fewer adverse events in the voclosporin group, despite a higher incidence of specific issues like decreased GFR and hypertension. - 25%… https://t.co/ToRu2rdErC https://t.co/uUXzNNuLDb

• https://x.com/i/web/status/1858608171926814731
• https://x.com/synovialjoints/status/1858608171926814731/photo/1